J&J psoriasis drug tops placebo, Humira in late stage study

(Reuters) – An experimental biotech drug developed by Johnson & Johnson proved more effective at clearing moderate to severe cases of the skin condition plaque psoriasis than a placebo or Abbvie Inc's big-selling Humira, according to data from a late stage study presented on Saturday. More than 73 percent of patients who received guselkumab experienced near complete skin clearance compared with 2.9 percent those who received a placebo. In the Humira group, nearly 50 percent of patients saw near complete skin clearance.

View original post here: 
J&J psoriasis drug tops placebo, Humira in late stage study